Press release from Companies
Publicerat: 2025-05-27 15:55:46
SensoDetect AB successfully participated in the 10th ADHD World Congress, highlighting its groundbreaking diagnostic technology—SensoDetect BERA—and engaging with global leaders in psychiatry, pediatrics, and neuroscience.
The congress, which brought together experts from across the world to discuss the latest advancements in Attention Deficit Hyperactivity Disorder (ADHD), served as a key platform for SensoDetect to present its objective, non-invasive method for neurodevelopmental diagnostics.
“The overwhelming interest and enthusiastic feedback from clinicians, researchers, and policy leaders at the congress confirmed what we’ve long believed: there is a global, urgent demand for accurate and early diagnostic tools for ADHD. SensoDetect BERA stands out as a groundbreaking solution ready to meet that demand. We’re excited to expand our market presence across Europe and are already engaging with a wealth of high-quality leads generated during the event. The momentum is clear — SensoDetect BERA is gaining recognition as a game-changer in neurodiagnostics,” says CEO Per-Anders (PA) Hedin.
Key highlights from SensoDetect at the congress:
Live demonstrations of the SensoDetect BERA system showing rapid, objective measurement of brainstem activity linked to ADHD.
Strong interest in the system’s potential for early screening and support for clinical decision-making—even in non-verbal or very young patients.
The SensoDetect BERA platform uses auditory brainstem responses to identify neuropsychiatric patterns with high precision, providing clinicians with actionable data in minutes. Its ease of use, minimal training requirement, and compatibility across age groups make it a powerful tool for modern diagnostics.
Next Steps
Following the congress, SensoDetect plans to expand collaborations with clinics, research centers, and regulatory stakeholders to support broader deployment and validation. The company is also preparing for market expansion into additional pediatric and neurodevelopmental diagnostic applications.
For more information or partnership inquiries, please contact:
PA Hedin, CEO Sensodetect AB
+46 (0)46 15 79 04
pa.hedin@sensodetect.com
SensoDetect AB är ett Med Tech AI-företag noterat på Spotlight stock market. Företaget grundades i Lund 2005, baserat på mer än 30 års forskning inom klinisk psyko akustik vid Institutionen för Neurovetenskap vid Lunds universitet. Inledningsvis låg fokus på patienter med schizofreni, då det är en sjukdom där hörselhallucinationer är ett vanligt symtom, men idag erbjuder företaget ett flertal andra tjänster inom produktområdena diagnostik, medicinering och hälsa. Produkterna används inom både privat och offentlig vård som komplement till andra observationer vid ADHD, schizofreni och autismutredningar, vid mätning av läkemedelseffekt samt vid screening av hörsel. SensoDetects unika och globalt patenterade teknik minskar den ekonomiska påverkan på hälso- och sjukvården samt samhället och ger patienter och dess anhöriga ett snabbare och säkrare resultat.
Mer info på https://www.sensodetect.com/